These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Shlyankevich J; Mehta NN; Krueger JG; Strober B; Gudjonsson JE; Qureshi AA; Tebbey PW; Kimball AB Am J Med; 2014 Dec; 127(12):1148-53. PubMed ID: 25149424 [TBL] [Abstract][Full Text] [Related]
4. Autoimmunity and autoimmune co-morbidities in psoriasis. Furue K; Ito T; Tsuji G; Kadono T; Nakahara T; Furue M Immunology; 2018 May; 154(1):21-27. PubMed ID: 29315555 [TBL] [Abstract][Full Text] [Related]
5. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. Lockshin B; Balagula Y; Merola JF J Am Acad Dermatol; 2018 Aug; 79(2):345-352. PubMed ID: 29477740 [TBL] [Abstract][Full Text] [Related]
6. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Puig L Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598 [TBL] [Abstract][Full Text] [Related]
7. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Ryan C; Kirby B Dermatol Clin; 2015 Jan; 33(1):41-55. PubMed ID: 25412782 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Krueger JG; Brunner PM Exp Dermatol; 2018 Feb; 27(2):115-123. PubMed ID: 29152791 [TBL] [Abstract][Full Text] [Related]
9. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Karbach S; Croxford AL; Oelze M; Schüler R; Minwegen D; Wegner J; Koukes L; Yogev N; Nikolaev A; Reißig S; Ullmann A; Knorr M; Waldner M; Neurath MF; Li H; Wu Z; Brochhausen C; Scheller J; Rose-John S; Piotrowski C; Bechmann I; Radsak M; Wild P; Daiber A; von Stebut E; Wenzel P; Waisman A; Münzel T Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2658-68. PubMed ID: 25341795 [TBL] [Abstract][Full Text] [Related]
10. [Psoriasis and cardiovascular risk factors]. Tal R; Pavlovsky L; David M Harefuah; 2012 Oct; 151(10):573-5, 605. PubMed ID: 23316664 [TBL] [Abstract][Full Text] [Related]
11. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model. Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960 [TBL] [Abstract][Full Text] [Related]
12. [Psoriasis, a systemic disease?]. Puig-Sanz L Actas Dermosifiliogr; 2007; 98(6):396-402. PubMed ID: 17663929 [TBL] [Abstract][Full Text] [Related]
13. Psoriasis and cardiovascular disorders. Ryan C; Menter A G Ital Dermatol Venereol; 2012 Apr; 147(2):179-87. PubMed ID: 22481581 [TBL] [Abstract][Full Text] [Related]
14. Psoriasis: comorbidities and associations. Farley E; Menter A G Ital Dermatol Venereol; 2011 Feb; 146(1):9-15. PubMed ID: 21317853 [TBL] [Abstract][Full Text] [Related]
15. Psoriasis as the marker of underlying systemic disease. Kourosh AS; Miner A; Menter A Skin Therapy Lett; 2008 Feb; 13(1):1-5. PubMed ID: 18357363 [TBL] [Abstract][Full Text] [Related]
16. Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting. Boehncke WH J Rheumatol; 2012 Feb; 39(2):441-4. PubMed ID: 22298277 [TBL] [Abstract][Full Text] [Related]